Hematological cancer patients more likely to have severe COVID-19

THURSDAY, Feb. 29, 2024 (HealthDay News) — For hematologic cancer patients, the likelihood of developing severe COVID-19 remains higher by mid-2022 despite vaccination, according to a study published online Feb. 23. Is. jama network open,

Sonia T. Anand, Ph.D., MPH, from the VA Boston Cooperative Studies Program, and colleagues reported a case study involving all patients with hematologic malignant neoplasms in the National Veterans Health Administration with severe acute respiratory syndrome coronavirus 2 (SARS). Did a control study. -CoV-2) infection after vaccination. Patients with severe COVID-19 (cases) versus non-severe COVID-19 (controls) were compared; Data from 6,122 patients were included, 21.3 percent of whom had severe COVID-19.

The researchers found that the likelihood of severe disease was higher with age (adjusted odds ratio). [aOR] per one-year increase, 1.05), treatment with antineoplastic or immune-suppressive drugs (for example, in combination with glucocorticoids: AOR, 2.32), and comorbidities (AOR per comorbidity, 1.35). Booster vaccination was associated with a lower likelihood of severe disease. Overall, 3.7 percent of patients with SARS-CoV-2 infection progressed to severe COVID-19 during the period after oral antiviral drugs became widely used in March 2022.

The authors write, “Although the benefit of antiviral treatment during non-severe disease cannot be quantified, the relatively low proportion of treated patients developing severe COVID-19 may be enough to encourage greater use.” Is.”

abstract/full text

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”